Successfully reported this slideshow.

Partnerships for Drug Delivery


Published on

IQPC’s Partnerships for Drug Delivery Conference was designed to help pharmaceutical, biotechnology and drug delivery companies to maximize deal making potentials and mitigate risks to achieve long-term sustainability. It will provide a check-list of real life considerations for deal-making and drug delivery technology application strategies in your organization. Join us in Philadelphia on April 26-28, 2010 as we review on the latest drug delivery partnerships.

Published in: Business, Technology
  • Be the first to comment

  • Be the first to like this

Partnerships for Drug Delivery

  1. 1. Register by March 12, 2010 and Presents receive up to $600 off! See page 8 for details. Discover Strategic Innovations Within Licensing, Patent Opportunities, Delivery Technologies and Alliance Management April 26-28, 2010 • Philadelphia, PA Participating Organizations Include: Highlights of This Program Include: • GlaxoSmithKline • Identifying successful factors and strategies for leveraging delivery • Pfizer, Inc. partnerships • Merck & Co. • Addressing patent opportunities in drug delivery concept • AstraZeneca • Leveraging alliance management into partnerships • Sanofi Aventis US • Using innovative drug delivery formulations to extend the product • Novo Nordisk lifecycle • Novartis • Discussing the needs and relationships of specialty pharma companies • Boehringer-Ingelheim with drug delivery companies • Baxter Healthcare • Improving bioavailability and superiority through advanced drug delivery systems • Coviden • Understanding the FDA requirements to streamline the process and • Purdue Pharma obtain fast track approvals for drug delivery products • Arsenal Medical Media Partners:
  2. 2. April 26-28, 2010 • Philadelphia, PA Dear Colleagues, Who will you meet at the conference: Drug delivery is an increasingly impo rtant sector within the pharmaceutica undergone rapid growth within the l industry, which has Vice Presidents, Directors, Associate last few years. Drug delivery technolo growth of pharmaceutical compani gies are driving Directors, Managers, Principals, es and boosting their revenue by exten profitable lifecycle through new form ding the product‘s Consultants, Business Leaders within: ulations, combinations and reposition ing. This conference is designed to help Drug Delivery pharmaceutical, biotechnology and companies maximize deal making drug delivery Licensing potentials and mitigate risks to achie sustainability. It will provide real life ve long-term considerations for deal-making and Business Development technology application strategies in drug delivery your organization. Product Design At this year’s Partnerships for Drug Delivery Conference, you will hear Technology Assessment and case study examples including 17+ in-depth sessions : • Reviewing the outcome of pharma New Product Development partnering across the industry over • Evaluating if licensing is a good optio the last 10 years n for drug delivery partnerships • Understanding the FDA requirements Life Cycle / Portfolio Management to streamline the process and obta approvals for drug delivery products in fast track Research & Development • Examining late stage successful and unsuccessful diabetes licensing oppo • Novel drug delivery technologies and rtunities Strategic Alliances therapeutics • Discussing the needs and relationsh ips of specialty pharma companies Regulatory Affairs companies with drug delivery • Integrating patent considerations into a deal making process Manufacturing Benefit from industry presentations and perspectives shared by AstraZene GlaxoSmithKline, Purdue Pharma, ca, Merck, Pfizer, Coviden, Novartis, Baxter, Sanofi Aven Boehringer-Ingelheim and many more tis, Novo Nordisk, Sponsorship and pharmaceutical, biotech and CRO industry experts. Exhibition 0pportunities This conference promises to be a netw orking and discussion-filled event ideas and solutions to help you prep leaving you with new Sponsorships and exhibits are excellent are for your next partnership or allian ce. opportunities for your company to Join us in Philadelphia and learn from showcase its products and services to high- the experts on these vital strategies and technolo level, targeted decision-makers attending gies! the Partnerships for Drug Delivery eractive Conference. Pharma IQ and IQPC help P.S Highly int e pre- companies like yours achieve important and informativ shops! sales, marketing and branding objectives by Simon Curtis rk setting aside a limited number of event Senior Conference Director, Phar conference wo details. sponsorships and exhibit spaces, all of maceutical IQ or Pharma IQ, a division of IQPC See page 3 f which are tailored to assist your organization in creating a platform to maximize its exposure at the event. For more information on sponsoring or For Registration Information and to Download the Complete Brochure exhibiting at the Partnerships for Drug Visit or Call 1-800-882-8684 Delivery Conference, please call Mario Matulich at (212) 885-2719 or 2 Register Online at or Call 1-800-882-8684
  3. 3. PRE-CONFERENCE WORKSHOPS Monday, 2010 April 26, 9:00am – 12:00pm (Registration at 8:30am) A Partnering with Venture Capitalists in the Declining Financial Market and Effective Partnering & Licensing Strategies to Identify Innovative Technologies for Life-Cycle Extension The American financial market has declined in past year. Fund raising and What Will Be Covered: venture capitalism within drug delivery has never been more important and • Examining existing financing colorations and how to get ready for challenging during these volatile market conditions. The most critical part wider global implications of life-cycle management strategies is to identify and leverage advanced • Discussing what venture capital expects from investments technologies. This workshop will guide you through the process of • Investigating how seed funding can be obtained through creative deal searching for and working with the scientific society more effectively. structures • Ascertaining effective partnering & licensing strategies to identify How You Will Benefit: innovative technologies for life-cycle extension • Learning how to raise funds in the global financial market • Understanding how to convince venture capital to invest in your deals Workshop Leader: • Identifying key areas for life-cycle management and pipeline extension Michael Lewis, Principal, Excend Consulting Group • Understanding how licensing is playing a key role in life-cycle management strategies 1:00pm – 4:00pm (Registration at 12:30pm – Lunch Included) B Legal Considerations for “Non-Lawyers” to Maximize Deal Making Potential Working with a legal team has been a headache for most business What Will Be Covered: development professionals in drug delivery deals. Speaking the same • Providing an update on recent FDA legislation on drug delivery language with the legal team and understanding their concerns are • Highlighting IP issues in drug delivery deals becoming more important than ever to ensure that you control the risks • Utilizing global licensing strategies to acquire drug delivery technology of the deals. • Discussing deal valuations from legal perspective How You Will Benefit: Workshop Leader to be announced.Please check • Understanding the legal framework of drug delivery technology for further details. • Knowing how to work with the legal team to manage patent issues in the deal making process • Building an innovative deal structure to achieve life cycle management CONFERENCE DAY ONE Tuesday, April 27, 2010 7:30 Registration and Coffee of failed alliances • The role of big pharma: Can pharma survive as a 8:30 Welcome Address and Chairperson’s Opening marketing vehicle rather than as an innovator? Remarks • Understanding if mega-mergers drive profits or stifle innovation: How can they be used as a tool for organic growth? 8:45 Opening Keynote Session: Evaluating the • Discussing novel approaches for the pharmaceutical industry to Successes of Pharma Partnering: Reviewing the ensure success in the next decade within the delivery partnering Outcome of Pharma Partnering Across the space Industry over the Past 10 Years Mahesh Chaubal, PhD • Determining if the current model will sustain or inhibit growth Director, Global R&D, Medication Delivery in future Baxter Healthcare • Identifying the successful partnerships and uncovering the cost 3 Register Online at or Call 1-800-882-8684
  4. 4. DAY ONE Continued... Effective Deal Management and Business Development Legal and Regulatory Perspectives on Drug Delivery Partnerships 9:30 Panel Discussion: The Voice from Big Pharma: Discussing Successful Factors and Strategies for Leveraging Drug 1:30 Successfully Acquiring a Biosimiliar in Drug Delivery Partnerships Delivery for Partnering • Providing advice on the decision making processes within large • Effectively tackling the approval process for biosimilars and pharmaceutical and biotech corporations addressing the challenges posed by the sophisticated • Exploring drivers and inhibitors in the deal making process for big pharma manufacturing processes of biologic drugs companies • Successfully partnering an agreement to develop and • Knowing what qualities to look for from your potential partnering commercialize a biosimiolar in development for the potential organization treatment of Gaucher’s disease • Identifying when and how to approach the right people within your • Passing Phase III clinical studies, and is preparing to complete a proposed partnering organization rolling New Drug Application (NDA) with the U.S. Food and • Understanding and overcoming the most common headaches of Drug Administration (FDA) partnerships • Facilitating the development and expediting the review of drugs Augustine Yee to treat rare conditions or diseases, as well as an Emergency Senior Director, Global Strategic Planning and Business Development Use Authorization AstraZeneca • Aiming to meet the needs of many patient populations, including David Arvan those affected by rare diseases both domestically and internationally Director, US Business Development Christopher Slavinsky AstraZeneca Assistant General Council, Established Products Brand Vijay Tammara Pfizer, Inc. Senior Director, Regulatory Affairs Merck & Co. 2:15 Panel Discussion: Addressing Patent Opportunities in Drug Delivery Concept 10:15 Morning Networking Break • Specialty pharma, drug delivery, biotech and even generic companies can all greatly benefit from careful and early strategic patent 11:00 Understanding if Licensing is a Good Choice For Drug planning concerning products they propose to bring to market Delivery Partnerships • Recognizing that new drug development is a high risk venture • Examining the impact to future collaborators, buyouts, or licensing which takes a great deal of time, has an exceptionally low success activities related to your project rate, and in the case of a successful new drug development • Discussing implications for manufacturing and scale-up activities • Identifying which people should be responsible for the technology that is • Examining important opportunities for patent protection that licensed should not be (but often are) neglected by specialty pharma, • Utilizing a contract manufacturing organization for your project impacting drug delivery and generic companies the licensing of technology • Establishing a successful patent lifecycle management team • Analyzing who will own newly invented • Identifying the patent landscape IP as the project scales-up • Beyond Big Pharma – Specialty Pharma, Branded and Non- • Discussing whether licensing is going to make you more or less competitive Branded Generics James Eshelby, PhD Balu Gupta Director, Strategic Alliances Associate Vice President, Head, CNS Patent Operations Pfizer, Inc. Sanofi-Aventis US 11:45 Panel Discussion: Leveraging Alliance Management into Wendy A. Petka, PhD, J.D. Partnerships Director & Senior Counsel, Intellectual Property • Leveraged alliance strategies to capitalize on technology and build Boehringer Ingelheim Corporation promising drug pipelines Christopher Slavinsky • Assigning responsibilities for alliance management within your own Assistant General Council, Established Products Brand decision-making structure Pfizer, Inc. • Cooperating with your drug delivery partners to avoid unanticipated challenges • Evaluating the mechanisms and business models to determine the deal 3:00 Understanding the FDA Requirements to value in the current competitive market Streamline the Process and Obtain Fast Track Approvals for Drug Delivery Products David H. Donabedian, PhD, MBA Innovative pharmaceutical companies are faced with Vice President, Strategic Alliances, US CEEDD unprecedented challenges to get approvals from the FDA as the GlaxoSmithKline regulations are significantly tightened. PJ Anand • Thinking through the FDA perspective to achieve more with less Executive Vice President, Corporate Development • Understanding the stages of regulatory approval Arsenal Medical, Inc • Streamlining the filing processes with proven drug superiority • Creating internal synergy to accelerate the process Haro Hartounian, PhD Chief Executive Officer Vijay Tammara Vyteris Senior Director, Regulatory Affairs Merck & Co. 12:30 Networking Luncheon 4 Register Online at or Call 1-800-882-8684
  5. 5. DAY ONE Continued... 3:45 Afternoon Networking Break 5:15 Panel Discussion: What is Restricting Big Pharma’s Involvement Diabetes Therapeutic Licensing Opportunities with Licensing & Partnering within the and Technology Assessment Diabetes Arena? • Discussing the successes and failures of past pharma and 4:15 Examining Late Stage Successful and Potential Diabetes delivery technology collaborations within the diabetes space Licensing Opportunities • Identifying and forecasting successes of the future product • Understanding future licensing opportunities within the diabetes and pipelines within a growing therapeutic area metabolic space • Aligning your proposed partner’s aims and goals with your own • Discussing what is required from smaller companies to promote their • Understanding the incentives for large companies to seek small successful clinical phase work further specialized external sources • Identifying successful investment opportunities within the diabetes licensing • Enhancing the likelihood of a successful scouting process market • The visibility in the pharmaceutical arena • Discussing future potential collaborative opportunities Thomas Landh Thomas Landh, Director, Strategy and Sourcing Director, Strategy and Sourcing Novo Nordisk Novo Nordisk 6:00 Chairperson’s Closing Remarks and 4:45 Technical Session: Updates within Novel Diabetes Drug End of Day One Delivery Technology This session will give three biotech companies who specialize within the diabetes drug delivery technology space the opportunity to deliver a 10 minute presentation showcasing their novel delivery technology to our audience of potential partners and investors. This is a must attend for Pharma, biotech and the investment community. Presentation areas will include: • Late stage rapid acting injectable insulin • Ultra rapid injectable insulin • Clinical phase transdermal basal insulin Contact Simon Curtis at for presentation opportunities CONFERENCE DAY TWO Wednesday, April 28, 2010 8:00 Registration and Coffee 9:30 The Use of Modified Formulation and Delivery Technologies to Repurpose Old Drugs 8:30 Welcome Address and Chairperson’s Opening • Gaining a current and focused overview of formulation Remarks technologies in the drug industry • Assessing and forecasting the future of innovation in the drug Maximizing Product Exposure formulations arena within the Marketplace • Understand the issues faced in aligning drug formulation with drug-delivery 8:45 Novel Delivery Technologies & Therapeutics • Improve the efficacy of chemical entities and deliver the desired • Using technology to deliver patient centric and personalized therapeutic effect of drugs, both novel and established therapeutic solutions • Addressing formulation issues which occur within the CNS arena • Evaluation of new modalities to enable data driven investments • Discussing advancements in technology, formulations being in technology developed enabling and benefiting technology transfer • Early integration of technology to maximize Balu Gupta the potential of and differentiation of products. Associate Vice President, Head, CNS Patent Operations • Building a portfolio of technologies that can be ‘plugged in‘ as Sanofi-Aventis US needed. Saran Kumar, PhD David Roberts Principal Fellow, Pharmaceutical & Analytical Development Director, External Business Operations Technical R&D Novartis Pharmaceuticals Corporation Novartis Institutes for BioMedical Research, Inc. Vijay Tammara Senior Director, Regulatory Affairs Merck & Co. 5 Register Online at or Call 1-800-882-8684
  6. 6. DAY TWO Continued... 10:15 Morning Networking Break Forming an Effective Alliance 11:00 Improving Bioavailability and Superiority 2:15 Discussing the Needs and Relationships of through Advanced Drug Delivery Systems Specialty Pharma Companies with Drug Delivery • Alterations in drug delivery produce substantial changes in the Companies bioavailability which may lead to significant improvement on • Examining the relationships between specialty pharma and drug efficacy and tolerability delivery technology companies • Leveraging advanced drug delivery systems to consistently • How specialty pharma creates and evaluates new product opportunities enhance patient compliance and overall drug effect is crucial for • Debating whether specialty pharma is the future for Drug product enhancement strategies Delivery technology companies • Examining the recent advancement of drug delivery systems Allen G. Downs • Analyzing the impact of drug delivery systems on bioavailability Senior Executive, Director, Licensing & Business Development • Sustaining product value and combating generics by launching Purdue Pharma L.P. the improved or next-generation Saran Kumar, PhD 3:00 Afternoon Networking Break Principal Fellow, Pharmaceutical & Analytical Development Novartis 3:30 Discussing the Strategic Benefits of Merging Two Commercial Pipelines and Putting in Place 11:45 Developing a Novel Active Transdermal Delivery Plans for Effective Integration System for Small Molecules and Peptides • Avoiding the main problems and issues with merging • Developed a proprietary active patch technology based on the commercial pipelines principle of iontophoresis • Discussing key points in technology transaction negotiation • Consisting of a miniaturized pre-programmed controller and a • Assisting technology transfer to your organization ready-to-use pre-filled patch • Uncovering examples of successful integration of commercial pipelines • Examining a novel technology in it’s ability to control the flux of • Identifying approaches for shortening extremely long product drug through the skin by application of small and precisely development cycles controlled electrical current • Evaluating shorter testing cycles and getting faster approvals for • Discussing numerous preclinical and clinical studies for peptides new compound entities (NCEs) and small molecules to demonstrate the safety and efficacy Mahesh Chaubal, PhD • Displaying completed Phase II clinical evaluation of the safety Director, Global R&D, Medication Delivery and efficacy of several dosage strengths Baxter Healthcare Haro Hartounian, PhD Chief Executive Officer 4:15 Integrating Patent Considerations into a Deal Vyteris Making Process • Confirming patentability of the potential drug delivery technology 12:30 Networking Luncheon and the patent protection scope of this new technology • Defining patent inventorship such as employee inventions, 1:30 Innovations in Modified Release Systems university collaborative research agreements and joint inventions • Developing products and formulation expertise for delayed • Conducting Freedom-To-Operate (FTO) to minimize the risks of release and extended/controlled release applications patent infringement • Supporting the demand of today’s pharmaceutical industry with Wendy A. Petka, PhD, J.D. oral modified release dosage forms Director & Senior Counsel, Intellectual Property • Improving patient compliance through dosage frequency alteration Boehringer-Ingelheim Corporation • Leveraging novel drug delivery technologies • Case Study: Timed release oral drug delivery system Allen G. Downs Senior Executive, Director, Licensing & Business Development Vishal K. Gupta, MBA, PhD Purdue Pharma L.P. Director, Pharmaceutical R&D Covidien 5:00 Chairperson’s Closing Remarks and Close of Conference 6 Register Online at or Call 1-800-882-8684
  7. 7. ABOUT OUR PARTNERS Drug Delivery Technology Website: Drug Delivery Technology publishes scientific articles, special features, and market news covering the science and business of drug delivery, formulation development, product life-cycle management, technology assessment, product development, contracting and licensing. Specialty Pharma is a self-contained featured section inside Drug Delivery Technology addressing the business strategies behind portfolio optimization, pipeline management, and partnering with contract service providers throughout the drug development process. Drug Delivery Technology is committed to advancing the science, technology, and business of pharmaceutical and biological delivery systems PharmaVOICE Website: PharmaVOICE magazine, reaching more than 17,500 U.S.-based life-sciences executives, is the forum that allows business leaders to engage in a candid dialogue on the challenges and trends impacting the industry. PharmaVOICE, and its supporting VIEW publications, provide readers with insightful and thought-provoking commentary in a multiple-perspective format through forums, topics, and articles covering a range of issues from molecule through market. PharmaVOICE subscribers are also kept abreast of the latest trends and information through additional media resources, including WebLinx Interactive WebSeminars, Podcasts, Videocasts, White Papers, E-Surveys and e-Alerts. Additionally, provides a comprehensive directory of products, services, and solutions for the life-sciences industry. To Raise Your VOICE, contact PharmCast Website: is the world leading website designed specifically for pharmaceutical, clinical and biotechnology professionals. brings up-to-date information on pharmaceutical patents, FDA, news, jobs and Buyer's Guide to our visitors. It was created and is maintained by pharmaceutical and biotechnology professionals. Visit and discover for yourself why it is so popular among professionals. Pharmaceutical Manufacturing Website: Pharmaceutical Manufacturing is devoted exclusively to drug manufacturing and scale-up and dedicated to sharing best practices that will help drug industry professionals improve product quality, ensure compliance, reduce cycle times, eliminate organizational and information silos and reduce time to market for new drugs, drugs that can actually be manufactured. CanBiotech Website: CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the Bio Outsourcing Asia© Publication. Read about opportunities in India, China, Malaysia, Singapore, Taiwan and more. 7 Register Online at or Call 1-800-882-8684
  8. 8. Discover Strategic Innovations Within Licensing, Patent Opportunities, Delivery Technologies and Alliance Management April 26-28, 2010 • Philadelphia, PA 5 EASY WAYS TO REGISTER: 1 Web: 2 Call: 1-800-882-8684 3 Email: (Email this form to or fax to 646-378-6025) 4 Fax: 1-646-378-6025 5 Mail: IQPC -535 5th Avenue, 8th Floor, YES! Please register me New York, NY 10017 ❑ Conference Only ❑ Conference + 1 Workshop ❑ A or ❑ B ❑ All Access Name ____________________________________________________________ Job Title _________________________________________________ Organization______________________________________________________ Approving Manager________________________________________ Address _____________________________________________ City________________________________________State__________Zip_________ Phone________________________________________________ E-mail_______________________________________________________________ ❑ Please keep me informed via email about this and other related events. ❑ Check enclosed for $_________ (Payable to IQPC) ❑ Charge my ❑ Amex ❑ Visa ❑Mastercard ❑ Diners Club Card #______________________________Exp. Date____/____ CVM Code______ ❑ I cannot attend, but please keep me informed of all future events. 16631.002/D/SC Registration Information Team Discounts: For information on team discounts, please contact IQPC Customer Service at 1-800-882-8684. Only one discount may be applied per registrant. Register and Pay Register and Pay Standard by March 12, 2010 by April 9, 2010 Price Details for making payment via EFT or wire transfer: JPMorgan Chase - Penton Learning Systems LLC dba Conference Only $1,199 $1,599 $1,799 IQPC: 957-097239 ABA/Routing #: 021000021 Save $600 Save $200 Reference: Please include the name of the attendee(s) and the event number: 16631.002 All Access $2,199 $2,599 $2,799 Payment Policy: Payment is due in full at the time of registration Save $698 Save $298 Save $98 and includes lunches and refreshment. Your registration will not be confirmed until payment is received and may be subject to Workshops $549 each $549 each $549 each cancellation. For IQPC’s Cancellation, Postponement and Substitution Policy, please visit A $99 processing charge will be assessed to all registrations not accompanied by credit card payment at the time of registration. ©2010 IQPC. All Rights Reserved. The format, design, content and arrangement of this brochure constitute a trademark of IQPC. MAKE CHECKS PAYABLE IN U.S. DOLLARS TO: IQPC Unauthorized reproduction will be actionable under the Lanham * CT residents or people employed in the state of CT must add 6% sales tax. Act and common law principles. 8 Register Online at or Call 1-800-882-8684